- Home
- GRND vs ACLX Comparison
GRND vs ACLX Comparison
Compare GRND & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- ACLX
- Stock Information
- Founded
- GRND 2009
- ACLX 2015
- Country
- GRND United States
- ACLX United States
- Employees
- GRND N/A
- ACLX N/A
- Industry
- GRND Computer Software: Prepackaged Software
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- ACLX Health Care
- Exchange
- GRND Nasdaq
- ACLX Nasdaq
- Market Cap
- GRND 4.0B
- ACLX 3.3B
- IPO Year
- GRND N/A
- ACLX 2022
- Fundamental
- Price
- GRND $23.17
- ACLX $55.17
- Analyst Decision
- GRND Strong Buy
- ACLX Strong Buy
- Analyst Count
- GRND 5
- ACLX 13
- Target Price
- GRND $20.60
- ACLX $110.82
- AVG Volume (30 Days)
- GRND 1.8M
- ACLX 726.2K
- Earning Date
- GRND 05-08-2025
- ACLX 05-08-2025
- Dividend Yield
- GRND N/A
- ACLX N/A
- EPS Growth
- GRND N/A
- ACLX N/A
- EPS
- GRND N/A
- ACLX N/A
- Revenue
- GRND $344,636,000.00
- ACLX $107,936,000.00
- Revenue This Year
- GRND $26.83
- ACLX N/A
- Revenue Next Year
- GRND $22.29
- ACLX $96.17
- P/E Ratio
- GRND N/A
- ACLX N/A
- Revenue Growth
- GRND 32.71
- ACLX N/A
- 52 Week Low
- GRND $8.95
- ACLX $47.88
- 52 Week High
- GRND $24.80
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- GRND 56.24
- ACLX 44.07
- Support Level
- GRND $22.43
- ACLX $47.86
- Resistance Level
- GRND $24.80
- ACLX $67.36
- Average True Range (ATR)
- GRND 0.74
- ACLX 4.14
- MACD
- GRND 0.13
- ACLX -0.64
- Stochastic Oscillator
- GRND 44.96
- ACLX 54.62
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.